How to Fight US Insurance Denials for Amyloidosis Treatment

Amyloidosis—both ATTR cardiomyopathy (wild-type and hereditary) and AL light-chain amyloidosis—now has life-extending therapies that slow disease progression, reduce hospitalizations, and improve quality of life. Yet insurance denials remain common, especially for newer agents like tafamidis (Vyndaqel/Vyndamax, FDA approved May 2019), acoramidis (Attruby, approved November 2024), and vutrisiran for ATTR-CM (Amvuttra, expanded indication March 2025). Insurers often cite cost (tafamidis exceeds $200,000 annually), demand exhaustive diagnostic proof to rule out AL amyloidosis, or declare newer drugs "not medically necessary" when older therapies exist. For AL amyloidosis, plans may deny daratumumab-containing regimens (D-VCd, FDA approved January 2021) or autologous stem-cell transplant (ASCT) by invoking overly strict staging criteria. This guide explains how to counter the most common denial templates with the specific evidence, policy language, and diagnostic documentation that win appeals.

---

Why Insurers Deny Amyloidosis Treatment

1. "Diagnosis not adequately documented" or "monoclonal protein not excluded"

The insurer demands an endomyocardial biopsy even when you have a Tc-99m-PYP scan showing Perugini grade 2 or 3 with heart-to-contralateral-lung (H/CL) ratio ≥1.5, or claims you have not definitively ruled out AL amyloidosis. This often appears as "need biopsy-proven ATTR" or "serum free light-chain ratio not documented."

2. "Not medically necessary—patient is NYHA Class I or too mild"

The plan argues that therapy should wait until you are "symptomatic enough," citing an internal threshold (e.g., NYHA Class III only) even though the FDA label and pivotal trials enrolled NYHA Class I–III. For AL amyloidosis, insurers sometimes say "watch and wait" if your Mayo stage is I, despite clear benefit from early plasma-cell–directed therapy.

3. "Experimental or investigational" for newer agents

Attruby (acoramidis) and Amvuttra for ATTR-CM are FDA approved but very recent (November 2024 and March 2025, respectively), so some plans have not yet updated medical policies and reflexively deny as "not established." Similarly, daratumumab-containing regimens for AL may be labeled "investigational" if the plan's policy predates the January 2021 FDA approval of Darzalex Faspro for AL amyloidosis.

4. "Step therapy—must try diflunisal (or other therapy) first"

The insurer requires you to fail an off-label generic TTR stabilizer (diflunisal, an NSAID) or an older therapy before approving tafamidis, acoramidis, or vutrisiran, even though diflunisal carries bleeding and renal toxicity risks and lacks an FDA indication. For AL, a plan may insist on CyBorD (cyclophosphamide-bortezomib-dexamethasone) before allowing daratumumab-based D-VCd, ignoring the ANDROMEDA trial's first-line design.

5. "Autologous stem-cell transplant not covered—patient too high-risk"

For AL amyloidosis, the plan cites a cardiac biomarker cutoff (NT-proBNP >5,000 pg/mL or Mayo stage III) to deny ASCT referral, even when your amyloidosis center deems you eligible based on performance status, organ function, and recent risk-adapted protocols.

---

The Citations Insurers Respect

When you appeal, name these guidelines, trials, and consensus documents by title and year. Vague statements like "studies show benefit" carry no weight; specific citations do.

ATTR Cardiomyopathy (ATTR-CM)

• ATTR-ACT trial (Maurer et al., NEJM 2018)—the pivotal placebo-controlled trial of tafamidis (Vyndaqel/Vyndamax) in 441 patients with ATTR-CM, showing 30 % relative reduction in all-cause mortality and reduced cardiovascular hospitalizations over 30 months.
• ATTRibute-CM trial (Kittleson et al., NEJM 2024)—phase 3 trial of acoramidis (Attruby) in 632 ATTR-CM patients, demonstrating non-inferiority to tafamidis on cardiovascular death/hospitalization and superior TTR stabilization (≥90 % tetramer stabilization) at 12 months.
• HELIOS-B trial (Solomon et al., NEJM 2024)—phase 3 RNAi study of vutrisiran (Amvuttra) 25 mg SC every 3 months versus placebo in 655 ATTR-CM patients, showing significant reduction in the composite of cardiovascular death and recurrent cardiovascular events, leading to the March 2025 FDA approval expansion.
• Gillmore et al. 2016 algorithm (Gillmore, Circ 2016)—non-biopsy diagnosis pathway for ATTR-CM: Perugini grade 2–3 PYP/DPD/HMDP uptake plus absence of monoclonal protein (normal serum and urine immunofixation and serum free light chains) allows diagnosis without endomyocardial biopsy. Widely adopted in ACC/AHA and European Society of Cardiology practice.
• Berk et al., JAMA 2013—randomized controlled trial of diflunisal 250 mg twice daily in 130 patients with ATTRv polyneuropathy or cardiomyopathy, showing modest slowing of neurologic progression and quality of life. Off-label and less potent than tafamidis, but useful to cite when arguing step therapy is inappropriate given renal/GI risks of an NSAID.
• APOLLO-B study—phase 3 trial of patisiran (Onpattro) in ATTR-CM was negative on the primary endpoint; patisiran remains FDA approved only for hATTR polyneuropathy (August 2018). Cite this to block an insurer's attempt to substitute patisiran for tafamidis in cardiomyopathy.
• CARDIO-TTRansform (ongoing)—phase 3 trial of eplontersen (Wainua) for ATTR-CM; as of this writing eplontersen is FDA approved only for hATTR-PN (December 2023). Mention the ongoing trial if the insurer suggests eplontersen as an "equivalent" substitute.

AL (Light-Chain) Amyloidosis

• ANDROMEDA trial (Kastritis et al., NEJM 2021)—phase 3 study of subcutaneous daratumumab + cyclophosphamide, bortezomib, dexamethasone (D-CyBorD or "D-VCd") versus CyBorD alone in 388 newly diagnosed AL patients, demonstrating superior hematologic complete response (53 % vs. 18 %) and cardiac/renal organ response. Led to FDA approval of Darzalex Faspro for AL amyloidosis on January 15, 2021.
• Palladini et al. 2015; Gertz et al. 2016 ASCT reviews—consensus that carefully selected low-risk AL patients (Mayo stage I–II, NT-proBNP <5,000 pg/mL, troponin and performance status acceptable) benefit from high-dose melphalan with autologous stem-cell rescue. Treatment-related mortality now <5 % in expert centers. Cite to counter blanket "too dangerous" denials.
• Kumar et al. 2012 (Mayo staging)—NT-proBNP ≥1,800 pg/mL and troponin T ≥0.025 ng/mL define Mayo stages I–III for AL; widely used to risk-stratify. Also cite Palladini NAC (National Amyloidosis Centre) staging for European cohorts.

Multi-society Guidelines

• ACC/AHA 2023 Heart Failure Guideline update—includes recommendation that ATTR-CM patients receive disease-modifying therapy (tafamidis) in addition to guideline-directed medical therapy for heart failure.
• European Society of Cardiology (ESC) 2023 Cardiomyopathy Guideline—endorses tafamidis for ATTR-CM and non-invasive diagnostic pathway when PYP-positive and monoclonal protein excluded.
• International Society of Amyloidosis (ISA) consensus recommendations—periodic updates on diagnosis and treatment; cite the most recent consensus statement available.

---

How to Argue Against Each Denial Reason

1. "Diagnosis not adequately documented" or "monoclonal protein not excluded"

What the insurer is really saying: "We're not convinced you have ATTR-CM and not AL, so we won't pay for an ATTR therapy."

Your counter-argument:

1. Attach your Tc-99m-PYP scan report showing Perugini grade 2 or 3 cardiac uptake and an H/CL ratio ≥1.5. State: "Under the Gillmore et al. 2016 non-biopsy diagnostic algorithm (Circulation 2016), published and endorsed by ACC/AHA, a positive PYP scan in the setting of heart failure with left-ventricular wall thickness ≥12 mm is diagnostic of cardiac ATTR when monoclonal protein has been excluded."

2. Document your AL work-up in a bullet list:

- Serum protein electrophoresis (SPEP): normal or monoclonal protein absent.

- Urine protein electrophoresis (UPEP): negative for monoclonal protein.

- Serum free light chains (sFLC): kappa/lambda ratio within normal range (typically 0.26–1.65).

- Serum and urine immunofixation: negative.

Append each lab report. Write: "Monoclonal protein has been definitively excluded per standard AL amyloidosis screening, satisfying the Gillmore 2016 criteria. Endomyocardial biopsy is not required and would add procedural risk without changing diagnosis or management."

3. For hereditary ATTR (ATTRv): attach TTR gene sequencing showing the pathogenic variant (e.g., V122I, V30M). For wild-type ATTR (ATTRwt), state "TTR genotyping: wild-type—no pathogenic variant detected."

4. Cite the FDA label: "Vyndaqel/Vyndamax is indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) to reduce cardiovascular mortality and cardiovascular-related hospitalization. The label does not require endomyocardial biopsy; it requires diagnosis of ATTR-CM, which has been established by PYP imaging and exclusion of AL per published guidelines."

5. If the insurer still demands biopsy, note any contraindications (anticoagulation for atrial fibrillation, frailty, patient refusal) and emphasize that the ATTR-ACT trial itself enrolled many patients via non-invasive diagnosis. Request an independent medical review or external appeal, citing that the plan's requirement contradicts current standard of care.

---

2. "Not medically necessary—patient NYHA Class I or too mild"

What the insurer is really saying: "Why treat now when the patient isn't sick enough yet?"

Your counter-argument:

1. FDA label and trial enrollment: "The ATTR-ACT trial enrolled patients with NYHA Class I, II, and III. The FDA-approved indication for tafamidis does not restrict use to Class III. Delaying therapy until I am Class III or IV means allowing irreversible cardiac amyloid deposition and increased mortality risk."

2. Cite ATTR-ACT subgroup analyses (presented at major cardiology meetings and in supplementary data): relative benefit of tafamidis was observed across all NYHA classes, and early treatment in Class I–II prevents progression to advanced heart failure.

3. Highlight biomarkers and objective measures: "Although I am currently NYHA Class II, my NT-proBNP is 4,820 pg/mL (normal <125), troponin is elevated at 0.067 ng/mL, my 6-minute walk distance is only 285 meters (expected >400 m for age), and my KCCQ quality-of-life score is 42 (severe impairment). These objective data demonstrate significant disease burden that will worsen without disease-modifying therapy."

4. Amyloidosis is progressive and irreversible: "ATTR amyloidosis does not stabilize spontaneously. Every month of delay allows further fibril deposition in the myocardium, conduction system, and valves. The goal of tafamidis/acoramidis is to halt deposition before I reach end-stage heart failure, at which point therapy is less effective."

5. For AL amyloidosis and the 'watch and wait' argument: "The ANDROMEDA trial enrolled newly diagnosed AL patients regardless of Mayo stage. Early, deep hematologic response with daratumumab-based therapy (D-VCd) prevents irreversible organ damage. AL amyloidosis organ involvement does not regress without eliminating the amyloidogenic light chain; waiting risks progression to dialysis-dependent renal failure or refractory heart failure."

---

3. "Experimental or investigational" (for newer agents)

What the insurer is really saying: "Our medical policy hasn't caught up to recent FDA approvals."

Your counter-argument (tailor to your drug):

For Attruby (acoramidis):

1. "Attruby (acoramidis) received FDA approval on November 22, 2024, for the treatment of ATTR-CM based on the ATTRibute-CM trial published in the New England Journal of Medicine (Kittleson et al., 2024). It is not experimental; it is a fully approved, commercially available therapy."

2. "The ATTRibute-CM trial randomized 632 patients and demonstrated non-inferiority to tafamidis on the primary composite endpoint of cardiovascular death and cardiovascular-related hospitalization, with superior TTR stabilization (≥90 % tetramer binding at 12 months). Twice-daily oral dosing may improve adherence compared to once-daily tafamidis."

3. Request that the plan update its medical policy or grant an exception: "Under [state insurance code or ERISA], a plan may not deny coverage solely because its policy has not been updated to reflect a recent FDA approval. I request immediate peer-to-peer review with a cardiologist familiar with ATTR-CM."

For Amvuttra (vutrisiran) ATTR-CM indication:

1. "Vutrisiran (Amvuttra) was granted FDA approval for ATTR-CM on March 20, 2025, based on the HELIOS-B trial (NEJM 2024, Solomon et al.), making it the first RNA-interference therapy approved for cardiac ATTR. It is not investigational."

2. "HELIOS-B enrolled 655 ATTR-CM patients (wild-type and hereditary) and met its primary endpoint, showing significant reduction in cardiovascular death and recurrent cardiovascular events with quarterly subcutaneous injection. This represents an alternative mechanism (TTR synthesis knockdown) to oral stabilizers and may be preferable in patients with [gastrointestinal intolerance, pill burden, or advanced disease]."

For Daratumumab (D-VCd) in AL amyloidosis:

1. "Subcutaneous daratumumab (Darzalex Faspro) was FDA approved for newly diagnosed AL amyloidosis on January 15, 2021, based on the ANDROMEDA trial. Labeling D-VCd as 'investigational' contradicts the FDA approval and published phase 3 evidence."

2. Attach the ANDROMEDA citation and FDA approval letter summary (available on FDA.gov). "The plan's policy appears to predate this approval. I request immediate escalation to a hematologist reviewer."

---

4. "Step therapy—must try diflunisal (or other agent) first"

What the insurer is really saying: "Try the cheap generic before we pay for the expensive brand."

Your counter-argument:

1. Diflunisal has no FDA approval for ATTR-CM and carries significant risks: "Diflunisal is a non-steroidal anti-inflammatory drug. The Berk et al. JAMA 2013 trial showed modest benefit in a mixed ATTRv cohort, but diflunisal increases bleeding risk (I am on apixaban for atrial fibrillation) and can worsen renal function (my eGFR is 48 mL/min). Requiring a trial of diflunisal is not evidence-based step therapy—it is a delay tactic that exposes me to avoidable toxicity."

2. Tafamidis (or acoramidis, vutrisiran) is first-line, FDA-approved, guideline-recommended therapy: "ACC/AHA 2023 Heart Failure Guideline and ESC 2023 Cardiomyopathy Guideline both recommend tafamidis as disease-modifying therapy for ATTR-CM. Neither endorses diflunisal as preferred initial treatment. Step therapy that contradicts evidence-based guidelines may violate state step-therapy transparency laws [cite your state law if applicable, e.g., California AB 2472] and [for Medicare Advantage] CMS Chapter 6 Part B Drug Coverage requirements."

3. For plans demanding trial of patisiran (Onpattro) or eplontersen (Wainua) before tafamidis: "Patisiran failed to meet its primary endpoint in the APOLLO-B ATTR-CM trial and is FDA approved only for hATTR polyneuropathy, not cardiomyopathy. Eplontersen is similarly approved for polyneuropathy only (December 2023); CARDIO-TTRansform results are not yet available. Mandating an off-label or non-indicated drug as step therapy is inappropriate and potentially dangerous."

4. Offer to do a peer-to-peer: "I request that my cardiologist [name], who specializes in amyloidosis, speak directly with the plan's medical director to explain why tafamidis/acoramidis/vutrisiran is the evidence-based first choice and why diflunisal is contraindicated in my case."

---

5. "Autologous stem-cell transplant not covered—patient too high-risk"

What the insurer is really saying: "Your cardiac biomarkers are too high; ASCT is too dangerous."

Your counter-argument:

1. Cite your amyloidosis center's assessment: "I am being evaluated at [Boston University Amyloidosis Center / Memorial Sloan Kettering / Mayo Clinic / Stanford Amyloidosis Center], a recognized center of excellence. My treating hematologist has determined I am a candidate for ASCT based on Mayo stage [I or II], performance status, NT-proBNP [state value, emphasize if <5,000 pg/mL], and absence of high-risk comorbidities."

2. Modern ASCT mortality is <5 % at experienced centers: "The plan's policy may cite outdated mortality figures. Gertz et al. 2016 and Palladini et al. 2015 reviews document that treatment-related mortality for AL ASCT at expert centers is now under 5 %, compared to >40 % in early series. Patient selection and peri-transplant supportive care have dramatically improved."

3. ASCT offers the deepest hematologic responses and best long-term survival in selected patients: "For eligible AL patients, high-dose melphalan with stem-cell rescue achieves hematologic complete response rates of 40–60 % and median overall survival exceeding 10 years (Palladini et al., Gertz et al.). Denying ASCT forces me onto chemotherapy alone, which has lower cure rates."

4. If the plan cites an NT-proBNP >3,000 pg/mL cutoff: "While historical studies used 5,000 pg/mL as a safety threshold, contemporary risk-adapted protocols incorporate additional factors—troponin, NYHA class, ejection fraction, and frailty indices. My care team has assessed all factors and deems transplant appropriate. I request external review by a hematologist with AL amyloidosis and transplant expertise."

5. NCCN and ASH guidelines support ASCT in selected AL patients; attach the relevant NCCN Multiple Myeloma/AL Amyloidosis guideline page or ASH educational materials.

---

What We Do

If your insurer has denied tafamidis, acoramidis, vutrisiran, daratumumab-based AL therapy, ASCT, or another amyloidosis treatment, we help you build a medical-record-backed appeal with the specific trial citations, guideline references, and diagnostic documentation that peer reviewers and external appeals boards respect. We work alongside your cardiologist or hematologist to translate clinical details—PYP scan results, monoclonal protein work-up, biomarkers, NYHA class, staging—into the language insurance medical directors understand. We also identify state-specific step-therapy laws, external review pathways, and expedited appeal options when time is critical. Amyloidosis is relentlessly progressive; every month of delay matters.

---

Sources

1. Maurer MS, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016. (ATTR-ACT trial)

2. Kittleson MM, et al. Acoramidis for transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;391(19):1745–1755. (ATTRibute-CM trial)

3. Solomon SD, et al. Vutrisiran for patients with transthyretin amyloidosis cardiomyopathy. N Engl J Med. 2024;391(22):2095–2106. (HELIOS-B trial)

4. Gillmore JD, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–2412.

5. Berk JL, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310(24):2658–2667.

6. Kastritis E, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385(1):46–58. (ANDROMEDA trial)

7. Palladini G, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers. J Clin Oncol. 2012;30(36):4541–4549.

8. Gertz MA, et al. Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc. 2008;83(10):1131–1138. (Foundational ASCT safety data)

9. Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2023 Update). Circulation. 2023;147(16):e895–e1032.

10. Arbelo E, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503–3626.

11. U.S. Food and Drug Administration. FDA approves first treatment for cardiomyopathy caused by transthyretin mediated amyloidosis. May 3, 2019. www.fda.gov/news-events/press-announcements

12. U.S. Food and Drug Administration. FDA approves Darzalex Faspro (daratumumab and hyaluronidase-fihj) for light chain amyloidosis. January 15, 2021.

13. U.S. Food and Drug Administration. FDA approves Attruby (acoramidis) for ATTR-CM. November 22, 2024.

14. U.S. Food and Drug Administration. FDA approves expansion of Amvuttra (vutrisiran) indication to include ATTR-CM. March 20, 2025.